Copyright
©The Author(s) 2015.
World J Gastroenterol. Dec 14, 2015; 21(46): 13030-13041
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13030
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13030
Figure 5 Expression of miR-210 and Yes1 in the different phases of the cell cycle.
A: Expression of miR-210 in HuH7 cells; B: Expression of Yes1 transcript in HuH7 cells; C and D: Western blot analysis of Yes1 protein expression (top panel) and in HuH7 cells (C) and HepG2 cells (D). Cells were enriched in the different cell cycle phases corresponding to G1 phase, S phase with thymidine double block treatment (Thy) or hydroxyurea treatment (HU), and G2/M phase with nocodazole treatment and mitotic shake-off (Noco); E: Western blot analysis of Yes1 protein expression (top panel) was performed with unsynchronized or nocodazole-treated (Noco) HuH7 cells following transfection with Inhibitor Negative Control (I-neg) or microRNA-210 Inhibitor (210-I). β-actin was used as the control for normalization (bottom panel). Yes1 expression was normalized to that of β-actin and the fold change was determined by comparison with the levels in G1-enriched cells (for C, D) or the unsynchronized cells transfected with I-neg (for E).
- Citation: Tan W, Lim SG, Tan TM. Up-regulation of microRNA-210 inhibits proliferation of hepatocellular carcinoma cells by targeting YES1. World J Gastroenterol 2015; 21(46): 13030-13041
- URL: https://www.wjgnet.com/1007-9327/full/v21/i46/13030.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i46.13030